Selective Nodal Irradiation of Regionally Advanced Non-small-cell Lung Cancer with Proton Therapy and IMRT: A Dosimetric Comparison
Overview
Pulmonary Medicine
Authors
Affiliations
Objectives: Evaluate the dosimetric impact of selective/elective nodal treatment with dose-escalated radiotherapy for regionally advanced non-small-cell lung cancer (NSCLC) using proton therapy (PT) or intensity-modulated radiotherapy (IMRT).
Methods: Five consecutive patients with regionally advanced NSCLC underwent treatment planning for high-dose involved-field (IF) treatment (positron emission tomography-positive gross disease) with or without selective/elective nodal irradiation, defined as the extended field (EF). Four treatment plans were developed for each patient: i) IMRT to treat IF to 74 Gy (IFrT); ii) IMRT to treat high-risk nodes to 44 Gy and IF to 74 Gy (EFrT); iii) PT to treat IF to 74CGE (IFpT); and iv) PT to treat high-risk nodes to 44CGE and IF to 74CGE (EFpT). High-risk nodes were defined as mediastinal, hilar, and supraclavicular lymph node stations adjacent to foci of PET-positive gross disease. The IMRT and PT plans were isoeffective. Dose to organs at risk (OARs), including the lung, esophagus, heart and spinal cord, were evaluated.
Results: The average IF clinical target volume (CTV) was 397 cc (344-428), while the average EF CTV was 642 cc (530-753 cc). Comparing IMRT with PT, mean lung dose reduced 3.4 Gy/CGE and 3.7 Gy/CGE; lung V20 reduced 4% and 5% for EF and IF, respectively.
Conclusions: Selective/elective nodal irradiation with protons reduces normal-lung exposure compared to selective/elective nodal irradiation with IMRT.
Kesarwala A, Ko C, Ning H, Xanthopoulos E, Haglund K, OMeara W Clin Lung Cancer. 2015; 16(3):237-44.
PMID: 25604729 PMC: 4410064. DOI: 10.1016/j.cllc.2014.12.001.
Yin L, Yu X, Ren Y, Gu G, Ding T, Lu Z Multidiscip Respir Med. 2013; 8(1):21.
PMID: 23506629 PMC: 3608960. DOI: 10.1186/2049-6958-8-21.